Other post-neoadjuvant treatment regimens including abemaciclib and olaparib have yielded better results, and these drugs may be the direction for enhanced treatment of HR+HER2-LN+ breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.